sorafenib has been researched along with vidarabine in 2 studies
Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (vidarabine) | Trials (vidarabine) | Recent Studies (post-2010) (vidarabine) |
---|---|---|---|---|---|
6,520 | 730 | 5,251 | 4,976 | 974 | 1,525 |
Protein | Taxonomy | sorafenib (IC50) | vidarabine (IC50) |
---|---|---|---|
Dipeptidyl peptidase 4 | Homo sapiens (human) | 0.062 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 2 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Andersson, BS; Champlin, RE; Li, Y; Liu, Y; Song, G; Valdez, BC | 1 |
Aymerich, M; Bataller, A; Camós, M; Colomer, D; Díaz-Beyá, M; Esteve, J; Garrote, M; López-Guerra, M; Oliver-Caldés, A; Vega-García, N | 1 |
2 other study(ies) available for sorafenib and vidarabine
Article | Year |
---|---|
Synergistic cytotoxicity of sorafenib with busulfan and nucleoside analogs in human FMS-like tyrosine kinase 3 internal tandem duplications-positive acute myeloid leukemia cells.
Topics: Adenine Nucleotides; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arabinonucleosides; Busulfan; Clofarabine; DNA Damage; Drug Synergism; fms-Like Tyrosine Kinase 3; Humans; Leukemia, Myeloid, Acute; Niacinamide; Phenylurea Compounds; Phosphorylation; Sorafenib; Tandem Repeat Sequences; Vidarabine | 2014 |
Early T-cell precursor lymphoblastic leukaemia: response to FLAG-IDA and high-dose cytarabine with sorafenib after initial refractoriness.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Dose-Response Relationship, Drug; Female; Granulocyte Colony-Stimulating Factor; Humans; Idarubicin; Male; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Sorafenib; Treatment Outcome; Vidarabine | 2019 |